Glucagon-like peptide-1 receptor agonists for obesity: Growing popularity met with growing questions over safety.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41533690.
- Also identified by DOI 10.1371/journal.pmed.1004871 and PMC identifier 12803457.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Glucagon-like peptide-1 (GLP-1)-based medications, such as semaglutide and tirzepatide, have transformed obesity care. However, rising use brings concerns about side effects, long-term outcomes, and unregulated products. Ensuring safe access requires oversight, monitoring, and coordinated clinical care.
Medical subject headings
- Anti-Obesity Agents
- Glucagon-Like Peptide-1 Receptor Agonists
- Obesity